BillionToOne: A Closer Look at the Biotech Stock Surge

BillionToOne, a biotech company based in Menlo Park, has seen its stock price soar. As of Friday, shares were trading at $130. 18, a significant jump from the initial public offering price of $60. This surge values the company at $5. 91 billion. The company recently raised $273 million by selling 4. 55 million shares, priced between $49 and $55 each. This was more than initially planned, showing strong investor interest. Analysts are optimistic about BillionToOne's future. They highlight the company's lead in prenatal screening and its promising pipeline of cancer tests. Piper Sandler, for instance, gave the stock an "overweight" rating and set a price target of $150. They described the company's oncology liquid biopsy products as "game-changing" for therapy selection and monitoring. J. P. Morgan also shared this optimism. They pointed to BillionToOne's pipeline, including a tissue-free minimal residual disease test expected in 2026, as a key driver for long-term growth. However, not all analysts are as bullish. Jefferies, which has a "hold" rating on the stock, noted that the current share price already reflects a lot of future growth. They acknowledged the company's strong technology but cautioned that success in cancer testing will take time. BillionToOne was founded in 2016. It develops non-invasive prenatal and oncology blood tests using proprietary single-molecule next-generation sequencing technology. The company's revenue has been growing rapidly. In the six months ended June 30, revenue rose nearly 82% from a year earlier. Gross profit more than doubled over the same period.